MedTrace Logo

TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)

NCT02117427 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2018-10-30

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.

Conditions

Interventions

BIOLOGICAL

MDGN201 TARGTEPO

Erythropoietin secreted by TARGTEPO transduced with MDGN201

Sponsors & Collaborators

  • Medgenics Medical Israel Ltd.

    collaborator INDUSTRY

  • Aevi Genomic Medicine, LLC, a Cerecor company

    lead INDUSTRY

Principal Investigators

  • Shany Blum, MD PhD · Aevi Genomic Medicine, LLC, a Cerecor company

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-27
Primary Completion
2016-06-30
Completion
2017-03-20

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117427 on ClinicalTrials.gov